Design of experiment (DoE)-based formulation design of bepotastine sustained-release tablet and in vitro-in vivo pharmacokinetic correlation

This publication has 25 references indexed in Scilit:

• The clinical pharmacology of non-sedating antihistamines
  Pharmacology & Therapeutics, 2017
• Second generation H1 - antihistamines interaction with food and alcohol—A systematic review
  Biomedicine & Pharmacotherapy, 2017
• Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis
  Expert Opinion on Pharmacotherapy, 2015
• Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects
  Clinical Drug Investigation, 2013
• Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs
  Drug Development and Industrial Pharmacy, 2012
• Safety considerations in the management of allergic diseases: focus on antihistamines
  Current Medical Research and Opinion, 2012
• Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate
  Current Medical Research and Opinion, 2010
• Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models
  Experimental Eye Research, 2010
• Multiple Peaking Phenomena in Pharmacokinetic Disposition
  Clinical Pharmacokinetics, 2010
• A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats
  International Journal of Pharmaceutics, 2007